340B Drug Pricing Program
Coverage of 340B Drug Pricing Program in the Nexus archive.
- Efforts to reform federal drug pricing program 340B continue with new report, proposed CMS rule
The 340B drug pricing program, designed to provide discounts to hospitals and clinics serving underserved populations, faces scrutiny due to misuse by some providers, including Richmond Community Hospital and Cleveland Clinic, which allegedly exploited the system for profit. Federal officials are proposing reforms via the 340B For Patients Act and a new CMS rule to reduce Medicare payments for 340B drugs.
- STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
The Pharmaceutical Research and Manufacturers of America is launching a seven-figure ad campaign targeting the 340B Drug Pricing Program, while the US Food and Drug Administration has seen an increase in rejection rates for cell and gene therapies. The program requires manufacturers to provide drugs at reduced prices to health providers caring for low-income patients. The ad campaign aims to manipulate the program's benefits.